• New ‘vaccine’ shows promise in early study

    New ‘vaccine’ shows promise in early study

    Published Date : 06-Aug-2020 9:04:47 IST

    Novavax said its experimental Covid-19 vaccine produced high levels of antibodies, according to initial data from earlystage clinical trial. The US firm said it could start a large pivotal Phase III trial as soon as late September, and added that it could produce 1 billion to 2 billion doses in 2021. Novavax research chief Gregory Glenn said the late-stage trial could glean enough data to obtain regulatory approvals as early as December.

Related Posts